Dishman Carbogen Amcis Ltd

For the third consecutive session, Dishman Carbogen Amcis Ltd has closed lower, culminating in a fresh 52-week low of Rs 147 on 23 Mar 2026. This marks a 14.14% decline over the last three days, underscoring persistent selling pressure despite a broader market environment that is also under strain.

For the fifth straight session, Dishman Carbogen Amcis Ltd closed lower, breaching its 52-week low at Rs 147 on 23 Mar 2026, marking a 14.14% decline over this losing streak and underperforming its sector by 4.2% today alone.

Dishman Carbogen Amcis Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 04 Feb 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 20 March 2026, providing investors with the latest insights into its performance and outlook.

Dishman Carbogen Amcis Ltd’s shares declined sharply to a new 52-week low of Rs.154.3 on 13 Mar 2026, marking a significant downturn amid broader market weakness and company-specific concerns. The stock has underperformed its sector and key indices, reflecting ongoing pressures on its financial and operational metrics.

Dishman Carbogen Amcis Ltd’s shares declined sharply to a new 52-week low of Rs.154.7 on 9 March 2026, marking a significant downturn amid broader market weakness and company-specific headwinds. The stock’s recent performance reflects ongoing concerns about its financial health and market positioning within the Pharmaceuticals & Biotechnology sector.

Dishman Carbogen Amcis Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 09 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Dishman Carbogen Amcis Ltd has reached a new 52-week low of Rs.161.85, marking a significant decline amid a broader market environment where the Sensex is trading positively. The stock’s recent performance reflects a series of challenges impacting its valuation and investor sentiment.

Dishman Carbogen Amcis Ltd’s stock touched a fresh 52-week low of Rs.165.35 today, marking a significant decline amid a sustained downward trend. The stock has underperformed both its sector and broader market indices, reflecting ongoing concerns about its financial health and market positioning.

Dishman Carbogen Amcis Ltd’s shares declined sharply to a new 52-week low of Rs.165.35 on 4 March 2026, marking a significant downturn amid broader market fluctuations and company-specific pressures. The stock has underperformed its sector and benchmark indices, reflecting ongoing concerns about its financial health and market positioning.

Dishman Carbogen Amcis Ltd has touched a fresh 52-week low of Rs.168 today, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical and biotechnology company’s shares have underperformed both the sector and broader market indices, reflecting persistent challenges in its financial and market performance.

Dishman Carbogen Amcis Ltd’s stock declined sharply to a new 52-week low of Rs.173.6 today, marking a significant downturn amid broader sector and market pressures. The pharmaceutical and biotechnology company’s shares underperformed the sector by 5.07% and closed well below key moving averages, reflecting ongoing concerns about its financial health and market positioning.

Dishman Carbogen Amcis Ltd recorded a robust intraday performance on 26 Feb 2026, surging to a day’s high of Rs 190.8, marking an 8.01% increase from its previous close. The stock outperformed its Pharmaceuticals & Biotechnology sector peers and the broader market, registering a 7.33% gain despite a subdued Sensex session.

Dishman Carbogen Amcis Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Dishman Carbogen Amcis Ltd’s stock touched a fresh 52-week low of Rs.175.4 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing concerns about its financial health and market positioning.

Dishman Carbogen Amcis Ltd’s stock price declined to a fresh 52-week low of Rs.177.35 today, marking a significant milestone in its ongoing downward trajectory. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market factors that have weighed on investor sentiment over the past year.

Dishman Carbogen Amcis Ltd’s stock reached a fresh 52-week low of Rs.179.6 today, marking a significant decline amid ongoing downward momentum. The stock has underperformed its sector and broader market indices, reflecting persistent pressures on its valuation and financial metrics.

Dishman Carbogen Amcis Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 February 2026, providing investors with the most recent and relevant data to assess the company’s outlook.

Dishman Carbogen Amcis Ltd recorded a robust intraday performance on 9 Feb 2026, surging to an intraday high of Rs 216, marking a significant 7.46% increase over the previous close. This sharp rise outpaced the broader market and sector indices, signalling a notable reversal after three consecutive days of decline.